1. India Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Vaidya Sane Ayurved Laboratories Limited

Vaidya Sane Ayurved Laboratories Limited

NNSE:MADHAVBAUG
146.45
INR
0.00
(0.00%)
1.75BMarket Cap
Vaidya Sane Ayurved Laboratories Limited
NSE:MADHAVBAUG
(National Stock Exchange of India)

Recent

price

146.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
59.44
71.56
49.72
172.26
94.33
94.46
85.51
101.25
- -
Revenue per Share
0.47
-0.53
0.37
8
4.6
1.88
6.79
8.51
- -
Basic EPS, GAAP
1.51
7.34
4.61
-37.57
-6.58
-11.8
16.41
-2.34
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.25
0.25
- -
- -
- -
Dividend per Share
8.35
7.82
9.29
34.13
38.48
52.89
59.5
83.03
83.03
Book Value per Share
6.93
6.75
8.86
33.14
36.09
45.65
47.88
71.05
71.05
Tangible Book Value per Share
11
11
11
4
11
11
11
11
11
Basic Weighted Avg Shares
625
752
523
747
992
993
899
1,069
- -
Sales/Revenue/Turnover
2.41
0.91
3.92
6.76
5.98
1.38
11.42
8.87
- -
Operating Margin (%)
16
22
24
23
26
31
42
61
- -
Depreciation Expense
5
-6
4
35
48
20
71
90
- -
Net Income, GAAP
43.75
- -
13.81
26.95
24.87
30.52
27.73
16.81
- -
Effective Tax Rate (%)
0.79
-0.74
0.75
4.64
4.87
1.99
7.94
8.41
- -
Profit Margin (%)
-90
-102
-67
130
149
197
187
332
332
Working Capital
- -
- -
- -
- -
- -
- -
15
26
26
LT Debt
88
82
98
359
405
556
626
873
873
Total Equity
- -
- -
5.6
14.54
11.29
2.06
10.33
9.69
- -
Return on Invested Capital (%)
- -
- -
5.23
15.15
12.83
4.4
11.75
11.73
- -
Return on Capital (%)
- -
-6.56
4.36
15.2
12.66
4.12
12.08
11.99
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
15
6
- -
LT Borrowings
15
- -
26
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
985
3,048
1,752

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
306
290
443
Cash, Cash Equivalents & STI
157
149
231
Accounts Receivable, Net
75
78
102
Inventories
38
34
36
Total Current Liabilities
120
111
111
Payables & Accruals
- -
- -
- -
ST Debt
15
6
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
73.93%
39.55%
Free Cash Flow
- -
-153.48%
-114.3%
Net Income, GAAP
- -
210.3%
25.93%
Sales/Revenue/Turnover
- -
17.05%
18.89%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
993
2025
- -
- -
899
2026
- -
- -
1,069

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.88
2025
- -
- -
6.79
2026
- -
- -
8.51

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.25
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Mobile-health Network Solutions (NASDAQ:MNDR)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG.NS) operates a chain of clinics and hospitals under the Madhavbaug brand, specializing in non-invasive Ayurveda-based treatments for chronic cardiac and lifestyle conditions; core services include heart disease reversal, diabetes reversal, hypertension management, obesity management, knee pain relief, panchakarma therapies, diagnostics, diet counseling, and physiotherapy. The company manufactures and sells in-house Ayurvedic medicines and nutritional products, such as Repoz Tablets, Pure Tanupushti Oil, Carbi Tablets, Ayurvedic Herbal Laxsa, and Dolorex Tablets, through its clinics, franchises, and hospitals. Incorporated in 1999 and headquartered in Thane, Maharashtra, India, it serves patients across approximately 360 clinics in states including Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Goa, Karnataka, Delhi, Punjab, Uttarakhand, West Bengal, and Chhattisgarh, complemented by three cardiac prevention and rehabilitation hospitals in Khopoli, Kondhali, and Visakhapatnam. In recent developments, the company completed the acquisition of Dynamic Remedies Private Limited and UV Ayurgen Pharma Private Limited in September 2023 for INR 50 million to bolster its product portfolio and manufacturing capabilities. It made Aaharshastra a wholly-owned subsidiary and entered a 70:30 profit-sharing memorandum of understanding (MoU) with a Malaysian partner in November 2025 to expand internationally. Vaidya Sane Ayurved Laboratories plans hospital expansions, including increased bed capacity at Khopoli, new facilities in Gujarat and North India, a state-of-the-art factory for enhanced production, cashless treatment empanelments with insurance providers and CGHS, and full NABH accreditation, alongside a preferential warrants issue of INR 102.48 crore to fund growth initiatives.